Literature DB >> 3928286

[14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis.

D A Henry, G Kitchingman, M J Langman.   

Abstract

Twenty-eight patients with histologically confirmed cirrhosis were followed for up to 3.8 years after [14C]aminopyrine breath analysis. Survival rates were calculated by life-table method and outcome analyzed by log rank test. A normal breath test score was associated with a higher probability of survival than a low score, although the difference was not statistically significant. A normal serum albumin was a better predictor of outcome. Survival curves constructed according to the results of breath analysis and serum albumin differed in that the former appeared to predict early survival and the latter late survival. For this reason, data were reanalyzed by subjects' results for both tests. A normal breath test score and a normal serum albumin was associated with a significantly higher probability of survival than an abnormal result for either test.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928286     DOI: 10.1007/bf01309509

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  THE GALACTOSE ELIMINATION CAPACITY IN RELATION TO CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH CIRRHOSIS.

Authors:  N TYGSTRUP
Journal:  Acta Med Scand       Date:  1964-03

2.  Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis.

Authors:  D Lebrec; P De Fleury; B Rueff; H Nahum; J P Benhamou
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

3.  Drugs as indicators of hepatic function.

Authors:  R A Branch
Journal:  Hepatology       Date:  1982 Jan-Feb       Impact factor: 17.425

4.  The [14C]-aminopyrine breath test. A comparison of different forms of analysis.

Authors:  D A Henry; G Sharpe; S Chaplain; S Cartwright; G Kitchingman; G D Bell; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

5.  Assessment of the (14C) aminopyrine breath test in liver disease.

Authors:  J Galizzi; R G Long; B H Billing; S Sherlock
Journal:  Gut       Date:  1978-01       Impact factor: 23.059

6.  Output of 14CO2 in breath after oral administration of (14C-methyl) aminopyrine in hepatitis, cirrhosis and hepatic bilharziasis: its relationship to aminopyrine pharmacokinetics.

Authors:  J Noordhoek; J Dees; E M Savenije-Chapel; J H Wilson
Journal:  Eur J Clin Pharmacol       Date:  1978-05-31       Impact factor: 2.953

7.  Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism.

Authors:  D A Henry; I A Macdonald; G Kitchingman; G D Bell; M J Langman
Journal:  Br Med J       Date:  1980-09-20

8.  [14C]Aminopyrine breath test in chronic liver disease: preliminary diagnostic implications.

Authors:  A V Burnstein; J T Galambos
Journal:  Dig Dis Sci       Date:  1981-12       Impact factor: 3.199

9.  The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis.

Authors:  J Lindskov
Journal:  Acta Med Scand       Date:  1982

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  11 in total

1.  Oral or intravenous lidocaine administration to perform megx test?

Authors:  E Giannini; F Botta; P Romagnoli; R Testa
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Preliminary studies of a canine 13C-aminopyrine demethylation blood test.

Authors:  E M Moeller; J M Steiner; D A Williams; P D Klein
Journal:  Can J Vet Res       Date:  2001-01       Impact factor: 1.310

3.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

4.  Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis.

Authors:  C Merkel; M Bolognesi; S Bellon; S Bianco; B Honisch; H Lampe; P Angeli; A Gatta
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

5.  Factors influencing survival at one year in patients with nonbiliary hepatic parenchymal cirrhosis.

Authors:  M Adler; J Van Laethem; A Glibert; M Gelin; N Bourgeois; P Vereerstraeten; M Cremer
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

6.  Use of a 13C-aminopyrine blood test: first clinical impressions.

Authors:  Deirdre Chiaramonte; Jörg M Steiner; John D Broussard; Keith Baer; Sheila Gumminger; Erik M Moeller; David A Williams; Renée Shumway
Journal:  Can J Vet Res       Date:  2003-07       Impact factor: 1.310

7.  Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?

Authors:  Christoph Herold; Sabine Regn; Marion Ganslmayer; Matthias Ocker; Eckhart G Hahn; Detlef Schuppan
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

8.  Hyperammoniemic coma in a patient with ureterosigmoidostomy and normal liver function.

Authors:  J L Van Laethem; F Gay; N Franck; A Van Gossum
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

9.  Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score.

Authors:  C Merkel; A Gatta; M Zoli; M Bolognesi; P Angeli; T Iervese; G Marchesini; A Ruol
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

10.  Relationship between 13C-aminopyrine breath test and the MELD score and its long-term prognostic use in patients with cirrhosis.

Authors:  Edoardo G Giannini; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2013-07-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.